136 hasil

ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025

Nicole Concin; Xavier Matías‐Guiu; David Cibula dkk.

The Lancet Oncology · 2025 · Inggris · OpenAlex Scopus

Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study

Anindo Saha; Joeran Sander Bosma; Jasper J. Twilt dkk.

The Lancet Oncology · 2024 · Inggris · OpenAlex Scopus

BACKGROUND: Artificial intelligence (AI) systems can potentially aid the diagnostic pathway of prostate cancer by alleviating the increasing workload, preventing overdiagnosis, and reducing the dependence on experienced radiologists. We aimed to investigate the performance of AI systems at…

Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data

Hyuna Sung; Rebecca L. Siegel; Mathieu Laversanne dkk.

The Lancet Oncology · 2024 · Inggris · OpenAlex Scopus

BACKGROUND: Previous studies have shown that colorectal cancer incidence is increasing among younger adults (aged 0·80), high (0·70-0·79), medium (0·55-0·69), and low (

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels; Yungan Tao; Lisa Francesca Licitra dkk.

The Lancet Oncology · 2024 · Inggris · OpenAlex Scopus

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Kohei Shitara; Sun Young Rha; Lucjan Stanislaw Wyrwicz dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Carcinogenicity of perfluorooctanoic acid and perfluorooctanesulfonic acid

Shelia Hoar Zahm; Jens Peter Bonde; Weihsueh A. Chiu dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis

Hisham Mohamed Mehanna; Miren Taberna; Christian von Buchwald dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

BACKGROUND: (p16) immunohistochemistry is the most widely used biomarker assay for inferring HPV causation in oropharyngeal cancer in clinical and trial settings. However, discordance exists between p16 and HPV DNA or RNA status in some patients with oropharyngeal cancer. We aimed to clearly…

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

James J. Harding; Jia Fan; Do‐Youn Oh dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Fred Saad; Noel William Clarke; Mototsugu Oya dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Global variations in lung cancer incidence by histological subtype in 2020: a population-based study

Yanting Zhang; Salvatore Vaccarella; Eileen Morgan dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep Maria Llovet; Masatoshi Kudo; Philippe Merle dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha; Do-Youn Oh; Patricio Eduardo Yanez dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study

Kristina Lång; Viktoria Josefsson; Anna-Maria Larsson dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

Eric Van Cutsem; Maria Di Bartolomeo; Elizabeth Catherine Smyth dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial

Adam M. Sonabend; Andrew R. Gould; Christina Amidei dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

John H. Strickler; Andrea Cercek; Salvatore Siena dkk.

The Lancet Oncology · 2023 · Inggris · OpenAlex Scopus

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

Dominique Farge; Corinne Frère; Jean M. Connors dkk.

The Lancet Oncology · 2022 · Inggris · OpenAlex Scopus

Cancer in sub-Saharan Africa: a Lancet Oncology Commission

Wilfred F. Ngwa; Beatrice Wiafe Addai; Isaac Folorunso Adewole dkk.

The Lancet Oncology · 2022 · Inggris · OpenAlex Scopus

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree; Peter James Ostler; H. van der Voet dkk.

The Lancet Oncology · 2022 · Inggris · OpenAlex Scopus

BACKGROUND: Localised prostate cancer is commonly treated with external beam radiotherapy and moderate hypofractionation is non-inferior to longer schedules. Stereotactic body radiotherapy (SBRT) allows shorter treatment courses without impacting acute toxicity. We report 2-year toxicity findings…

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard; François-Clément Bidard; Anne‐Claire Hardy‐Bessard dkk.

The Lancet Oncology · 2022 · Inggris · OpenAlex Scopus